专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09487574B2 Antigen specific multi epitope vaccines 有权
标题翻译：抗原特异性多表位疫苗
公开(公告)号：US09487574B2
公开(公告)日：2016-11-08
申请号：US12442495
申请日：2007-09-23
申请人： Lior Carmon
发明人： Lior Carmon
IPC分类号： A61K39/00 , C07K14/74 , C07K14/47
CPC分类号： A61K39/0011 , A61K39/00 , A61K2039/5154 , A61K2039/55522 , A61K2039/572 , C07K14/4727 , C07K14/4748 , C07K14/70539
摘要： The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.
摘要翻译：本发明涉及由肿瘤相关抗原或蛋白质的信号肽结构域组成的癌症疫苗。本发明的肽疫苗的特征在于具有在群体中高度丰富的多个MHC I类和II类表位。因此，这些疫苗可能对大多数接种疫苗的群体中的靶蛋白产生强烈的，全面的免疫应答，从而诱导针对表达这种靶蛋白的肿瘤的免疫反应。具体地，本发明涉及由粘蛋白（MUC1），BAGE-1或ARMET的信号肽结构域组成的肽疫苗及其用于治疗表达粘蛋白（MUC1），BAGE-1或ARMET的癌症的用途。

2. 发明申请

US20190216912A1 ANTIGEN SPECIFIC MULTI EPITOPE-BASED ANTI-INFECTIVE VACCINES 审中-公开
公开(公告)号：US20190216912A1
公开(公告)日：2019-07-18
申请号：US16371020
申请日：2019-03-31
申请人： Lior CARMON , VAXIL BIOTHERAPEUTICS LTD.
发明人： Lior CARMON
IPC分类号： A61K39/04
CPC分类号： A61K39/04 , A61K2039/6031 , A61K2039/6068 , A61K2039/6075 , Y02A50/41 , Y02A50/412 , Y02A50/414
摘要： The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.

3. 发明授权

US09642903B2 Antigen specific multi epitope-based anti-infective vaccines 有权
公开(公告)号：US09642903B2
公开(公告)日：2017-05-09
申请号：US13384286
申请日：2010-07-15
申请人： Lior Carmon
发明人： Lior Carmon
IPC分类号： A61K39/12 , A61K39/00 , A61K31/04 , A61K39/09 , A61P37/04 , A61K39/04
CPC分类号： A61K39/04 , A61K2039/6031 , A61K2039/6068 , A61K2039/6075 , Y02A50/41 , Y02A50/412 , Y02A50/414
摘要： Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.

4. 发明申请

US20140220028A1 ANTIBODIES DIRECTED AGAINST SIGNAL PEPTIDES, METHODS AND USES THEREOF 有权
标题翻译：针对信号肽的抗体，其方法和用途
公开(公告)号：US20140220028A1
公开(公告)日：2014-08-07
申请号：US14344837
申请日：2012-09-13
申请人： Lior Carmon , Riva Kovjazin
发明人： Lior Carmon , Riva Kovjazin
IPC分类号： C07K16/28 , G01N33/569
CPC分类号： C07K16/28 , G01N33/5695 , G01N33/56966 , G01N33/57492 , G01N2333/4725
摘要： Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.
摘要翻译：提供了使用针对各种疾病相关多肽的信号肽（SP）结构域的抗体的方法。这些抗SP抗体检测这些SP结构域的细胞表面表达，并用于诊断和/或治疗的方法。提供了一种用于确定治疗患有疾病的受试者的适合性的方法，由此检测特定SP的细胞表面表达表明受试者将受益于针对该SP的治疗。此外，提供了基于内生产生的抗SP抗体的检测来诊断疾病的方法。

5. 发明申请

US20100074925A1 ANTIGEN SPECIFIC MULTI EPITOPE VACCINES 有权
标题翻译：抗原特异性多抗原疫苗
公开(公告)号：US20100074925A1
公开(公告)日：2010-03-25
申请号：US12442495
申请日：2007-09-23
申请人： Lior Carmon
发明人： Lior Carmon
IPC分类号： A61K39/00 , C07H21/04 , C12N5/00 , C07K7/06 , A61P35/00
CPC分类号： A61K39/0011 , A61K39/00 , A61K2039/5154 , A61K2039/55522 , A61K2039/572 , C07K14/4727 , C07K14/4748 , C07K14/70539
摘要： The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.
摘要翻译：本发明涉及由肿瘤相关抗原或蛋白质的信号肽结构域组成的癌症疫苗。本发明的肽疫苗的特征在于具有在群体中高度丰富的多个MHC I类和II类表位。因此，这些疫苗可能对大多数接种疫苗的群体中的靶蛋白产生强烈的，全面的免疫应答，从而诱导针对表达这种靶蛋白的肿瘤的免疫反应。具体地，本发明涉及由粘蛋白（MUC1），BAGE-1或ARMET的信号肽结构域组成的肽疫苗及其用于治疗表达粘蛋白（MUC1），BAGE-1或ARMET的癌症的用途。

6. 发明授权

US11135277B2 Antigen specific multi epitope-based anti-infective vaccines 有权
公开(公告)号：US11135277B2
公开(公告)日：2021-10-05
申请号：US16508605
申请日：2019-07-11
申请人： Lior Carmon , VAXIL BIOTHERAPEUTICS LTD.
发明人： Lior Carmon
IPC分类号： A61K39/04 , A61K39/00 , A61K39/02 , A61K39/09 , C07K14/315
摘要： The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.

7. 发明授权

US10245309B2 Antigen specific multi epitope-based anti-infective vaccines 有权
公开(公告)号：US10245309B2
公开(公告)日：2019-04-02
申请号：US15588887
申请日：2017-05-08
申请人： Lior Carmon , VAXIL BIOTHERAPEUTICS LTD.
发明人： Lior Carmon
IPC分类号： A61K39/00 , A61K39/395 , C07K16/28 , C07K14/705 , C12N9/02 , A61K39/04
摘要： The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.

8. 发明授权

US07906620B2 Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines 失效
标题翻译：肿瘤相关抗原，其肽，以及抗肿瘤疫苗的用途
公开(公告)号：US07906620B2
公开(公告)日：2011-03-15
申请号：US10524787
申请日：2003-07-28
申请人： Lea Eisenbach , Boaz Tirosh , Lior Carmon , Arthur Machlenkin , Adrian Paz , Esther Tzehoval , Matityahu Fridkin
发明人： Lea Eisenbach , Boaz Tirosh , Lior Carmon , Arthur Machlenkin , Adrian Paz , Esther Tzehoval , Matityahu Fridkin
IPC分类号： A61K39/00 , A61K48/00 , C07K14/82 , C12N5/08
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , C07K14/4748 , C07K14/705 , C07K14/723
摘要： The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.
摘要翻译：本发明涉及从前列腺特异性G蛋白偶联受体（PSGR）获得的结肠和前列腺肿瘤相关的抗原肽，前列腺的六跨膜上皮抗原（STEAP）和由在结肠癌细胞中过表达的基因编码的蛋白质，例如人1 -8D干扰素诱导的跨膜蛋白2.本发明还涉及编码肿瘤相关抗原肽和药物组合物的多核苷酸，其优选为抗肿瘤疫苗组合物，其含有肿瘤相关抗原，至少一种肿瘤相关抗原肽，或其编码多核苷酸作为活性成分。可将药物组合物施用于有需要的患者，以治疗或抑制结肠癌或前列腺癌的发生。

9. 发明申请

US20090275634A1 ANTISENSE OLIGONUCLEOTIDES AGAINST ACETYLCHOLINESTERASE FOR TREATING INFLAMMATORY DISEASES 审中-公开
标题翻译：用于治疗炎症性疾病的抗乙酰胆碱酯酶的抗体寡核苷酸
公开(公告)号：US20090275634A1
公开(公告)日：2009-11-05
申请号：US12296455
申请日：2007-03-29
申请人： Eli Hazum , Lior Carmon
发明人： Eli Hazum , Lior Carmon
IPC分类号： A61K31/7052 , A61P29/00
CPC分类号： C12N15/1137 , A61K31/7105 , C12N2310/11 , C12N2310/321 , C12Y301/01007 , C12N2310/3521
摘要： The present invention relates to novel uses of antisense oligonucleotides targeted to the coding region of acetylcholinesterase (AChE) for treating inflammatory disorders other than inflammatory disorders of the central nervous system or the peripheral nervous system innervating voluntary muscles. More particularly, the present invention relates to uses of antisense oligodexoynucleotides targeted to AChE mRNA for treating inflammatory disease of the gastrointestinal tract including inflammatory bowel disease.
摘要翻译：本发明涉及靶向乙酰胆碱酯酶（AChE）编码区的反义寡核苷酸的新用途，用于治疗除中枢神经系统炎症性疾病或支配自愿肌肉的周围神经系统之外的炎症性疾病。更具体地，本发明涉及靶向AChE mRNA的反义寡核苷酸用于治疗胃肠道炎症性疾病（包括炎症性肠病）的用途。

10. 发明授权

US07531629B2 Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
标题翻译：肿瘤相关抗原肽及其与抗肿瘤疫苗的使用
公开(公告)号：US07531629B2
公开(公告)日：2009-05-12
申请号：US11391476
申请日：2006-03-29
申请人： Lea Eisenbach , Lior Carmon , Boaz Tirosh , Adrian Paz , Matityahu Fridkin
发明人： Lea Eisenbach , Lior Carmon , Boaz Tirosh , Adrian Paz , Matityahu Fridkin
IPC分类号： C07K14/00 , A61K38/00
CPC分类号： C12N9/6445 , A61K39/00 , A61K48/00 , C07K14/47 , C07K14/4727 , C07K14/705 , C12N9/16
摘要： The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.
摘要翻译：本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式